CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04584255
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:32.880049+00:00
Published At: 2025-07-28T00:00:00+00:00
Record Updated At: 2025-07-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Stage I Breast Cancer", "Stage II Breast Cancer", "Stage III Breast Cancer", "Breast Cancer", "HER2-negative Breast Cancer", "Germline BRCA1 Gene Mutation", "Germline BRCA2 Gene Mutation", "Deleterious PALB2 Gene Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-07-28"
protocolSection.identificationModule.nctId: "NCT04584255"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.